

Author Index
Volume 49
January-June 1994

- Aedo, A-R, 139
 Amatya, R., 231
 Andersson, K., 56
 Arrais, P.S., 101
 Bai, X-m, 245
 Bansode, F.W., 601
 Bassol, S., 441
 Beier, S., 275
 Blode, H., 255
 Bocciolone, L., 47
 Bokström, H., 115
 Bourinbaier, A.S., 131
 Caldwell, A.D.S., 1
 Cekan, S.Z., 139
 Chakrabarty, J., 171
 Chez, R.A., 125
 Chilvers, C., 211
 Coêlho, H.L., 101
 Coibion, M., 571
 Cookson, K.M., 335
 Czeizel, A.E., 565
 d'Arcanguez, C., 291
 de Fátima Cruz, M., 101
 Dhar, J.D., 609
 Dhawan, S., 161
 Dorflinger, L.J., 455
 Dwivedi, A., 609
 El-Husseini, M., 469
 El-Nahal, N., 469
 El-Rafaey, H., 111
 Everaerd, W.Th.A.M., 73
 Fajans, P., 509, 527
 Farr, G., 231
 Fauveau, V., 171
 Ferraroni, M., 47
 Fioretti, P., 33, 579
 Fotherby, K., 1
 Fraser, I.S., 399
 Fruzzetti, F., 579
 Garde, S.V., 593
 Garza-Flores, J., 347, 441
 Gaspard, U.J., 571
 George, S., 125
 Gerber, S., 557
 Giwa-Osagie, O.F., 421
 Gonzaga, S.L., 101
 Gordon, L., 557
 Günzel, P., 303
 Hall, P.E., 489
 Hamad, E.E., 265
 Hassan, E.O., 469
 Hatcher, R.A., 551
 Hendrick, J-C, 571
 Huang, T., 151
 ICMR Task Force on Hormonal Contraception, 87
 Ishwad, P.C., 593
 Johannisson, E., 139
 Jordan, A., 189
 Kirkman, R.J.E., 33
 Koetsawang, S., 387
 Kuhn, W., 255, 275
 Landgren, B-M, 139
 La Vecchia, C., 47, 223
 Lee-Huang, S., 131
 Leher, Ph., 73
 Lopez, M., 557
 Lubis, F., 509, 527
 Luchine, L., 101
 Mahmoud, E.A., 265
 Mahler, M., 255
 Mardh, P-A, 265
 Meirik, O., 185
 Norström, A., 115
 O'Brien, W.F., 125
 Oddens, B.J., 73
 Odland, V., 56
 Olsson, S-E, 265
 Parazzini, F., 47
 Pedersen, J.H., 33
 Pisake, L., 203
 Puri, C.P., 593
 Radestad, A., 115
 Ricci, C., 579
 Roberts, H.E., 33
 Rubessa, S., 47
 Rybo, G., 56
 Salway, S., 171

Author Index

- Sang, G-w, 361
Sarma, S.P., 551
Seibert, B., 303
Setty, B.S., 609
Sharma, M.G., 161
Sheth, A.R., 593
Shi, W-l, 245
Simmons, R., 509, 527
Skegg, D.C.G., 435
Spellacy, W.N., 125
Srivastava, A., 609
Talwar, G.P., 161
Teixeira, A.C., 101
Templeton, A., 111
Tognoni, G., 101
Toppozada, M.K., 293
Tozzi, L., 47
Tsibris, A.M.N., 125
Tsibris, J.C.M., 125
UNDP/UNFPA/WHO World Bank Special Programme of Research, Development and Research Training in Human Reproduction: IUD Research Group, 543
Upadhyay, S., 161
van den Brûle, F.A., 571
Verner, H.M., 73
Visser, A.Ph., 73
Wang, J-d, 245
Westhoff, C., 557
WHO Task Force on Long-Acting Systemic Agents for Fertility Regulation, 421
WHO Task Force on Research on Introduction and Transfer of Technologies for Fertility Regulation, 489
Zhang, G-q, 245
Zhang, S., 151

Subject Index **Volume 49** **January–June 1994**

- Acceptability, monthly combined injectable contraceptives, 469
- Anti-HIV activity, spermicides, 131
- Antichlamydial activity, cervical secretions, 265
- Antiprogesterin ZK 98.199, immunocytochemical study (monkey), 593
- Antiviral activity, spermicides, 131
- Bioavailability of levonorgestrel, ethinyl estradiol + norgestimate, 255
- Biological profile, CDRI 85/287 analogues (rat), 1
- Bleeding patterns, monthly combined injectable contraceptives, 399
- Breast cancer risk, DMPA, 211
- Carbohydrate metabolism, ethinyl estradiol + gestodene, 125
- CDRI 85/287 analogues,
 - anti-implantation activity (rat), 609
 - estrogenic/antiestrogenic activity (rat), 609
- Cervical neoplasia risk, DMPA, 223
- Cervical secretions, antichlamydial activity, 265
- Cervical smooth muscle,
 - effect of progesterone, 115
 - effect of RU 486, 115
- Clinical efficacy, low-dose combined OCs, 1
- Coagulation system, use of OCs by smoking vs nonsmoking women, 579
- Combined injectable contraceptives,
 - existing formulations, 293
 - pharmacodynamic effects, 361
 - pharmacokinetics, 347
- Congenital limb deficiency risk, contraceptive pill use, 565
- Contraceptive attitudes, Great Britain, 73
- Contraceptive choice, monthly combined injectable contraceptive introductory trial, 509
- Contraceptive effects, intrauterine neem oil treatment (monkey), 161
- Contraceptive methods, relation to endometriosis, 47
- Contraceptive pill use, risk of congenital limb deficiency, 565
- Contraceptive service delivery, monthly combined injectable contraceptive introductory trial, 527
- Contraceptive use, Great Britain, 73
- Contraindications and precautions, monthly combined injectable contraceptives, 455
- Copper T 200, 231
- Copper T 380A, 231, 543
- Copper-releasing IUD, 56
- Depot-medroxyprogesterone acetate (DMPA),
 - cervical neoplasia risk, 223
 - toxicology, 189
- Discontinuation, monthly combined injectable contraceptives, 387
- DMPA (depot-medroxyprogesterone acetate)
- DMPA and cancer risk, 203, 211
- DMPA safety, 185
- Efficacy, monthly combined injectable contraceptives, 387
- Emory removal method, NORPLANT® implants, 551
- Endometrial cancer risk, DMPA, 203
- Endometriosis, relation to contraceptive methods, 47
- Ethinyl cypionate + depot-medroxyprogesterone acetate, 335, 361
- Ethinyl valerate, animal toxicity studies, 303
- Ethinyl valerate + norethisterone enanthate, 303, 361
- Ethinyl estradiol + desogestrel, 1, 33
- Ethinyl estradiol + gestodene, 11, 33, 125
- Ethinyl estradiol + levonorgestrel, 1
- Ethinyl estradiol + norethisterone, 1
- Ethinyl estradiol + norgestimate, 1
- Fertility return, monthly combined injectable contraceptives, 441

¹NORPLANT® is a registered trademark of the Population Council, Inc.

Subject Index

- Fibronectin, isolation and purification, 151
- Gossypol, antiviral activity, 131
- Gossypol acetate, effect on ovary (bat), 601
- Gramicidin, antiviral activity, 131
- Haemostasis profile, use of OCs by smoking
vs nonsmoking women, 579
- HIV (human immunodeficiency virus)
- Hormone levels, effect of RU 486, 245
- Immune complexes, effect of oral contraceptives, 571
- Injectable contraceptive,
acceptability, 469
bleeding patterns, 399
cervical neoplasia risk, 223
contraindications and precautions, 455
depot-medroxyprogesterone acetate, 185,
189, 203, 211, 223
discontinuation, 387
efficacy, 387
estradiol cypionate + depot-medroxy-
progesterone acetate, 335
estradiol valerate + norethisterone enan-
thate, 303
introductory trials, 489, 509, 527
metabolic effects, 421
neoplasia risk, 435
once-a-month combined formulations, 293
pharmacodynamic effects, 361
pharmacokinetics, 347
return of ovulation, 441
- Intrauterine device (IUD),
copper T 200
copper T 380A, 231, 543
copper-releasing, 56
levonorgestrel-releasing, 56
Multiload 375, 543
- Intrauterine neem oil treatment (monkey),
161
- Introductory trials,
low-dose OC, 171
monthly combined injectable contracep-
tives, 489, 509, 527
- IUD (intrauterine device)
- Levonorgestrel-releasing IUD, 56
- Levonorgestrel-releasing vaginal ring, 139
- Low-dose vs standard-dose OCs, 171
- Metabolic effects,
low-dose combined OCs
monthly combined injectable contracep-
tives, 421
- Mifepristone (RU 486)
- Misoprostol, 101
- Monthly combined injectable contraception,
293, 303, 335, 347, 361, 387, 399, 421,
435, 441, 455, 469, 489, 509, 527
- Multiload 375, 543
- Neem oil treatment, intrauterine (monkey),
161
- Neoplasia risk, monthly combined injectable
contraceptives, 435
- Nonoxynol-9, antiviral activity, 131
- Norethisterone enanthate, animal toxicity
studies, 303
- NORPLANT® implants, 551, 557
- Nova T, 56
- Oral contraceptive (OC),
effect on haemostasis profile, 579
effect on immune complexes, 571
ethinyl estradiol + desogestrel, 1, 33
ethinyl estradiol + gestodene, 1, 33, 125
ethinyl estradiol + levonorgestrel, 1, 255
ethinyl estradiol + norethisterone, 1
ethinyl estradiol + norgestimate, 1, 255
low-dose vs standard-dose, 171
- Ovarian cancer risk, DMPA, 203
- Ovary, effect of gossypol acetate (bat), 601
- Ovulation return, monthly combined in-
jectable contraceptives, 441
- Periconceptional contraceptive pill use, 565
- Pharmacodynamic effects, combined in-
jectable contraceptives, 361
- Pharmacokinetic parameters, progestogens, 1
- Pharmacokinetic/pharmacodynamic profile,
estradiol cypionate + depot-medroxy-
progesterone acetate, 361
estradiol valerate + norethisterone enan-
thate, 361
- Pharmacokinetics,
combined injectable formulations, 347
ethinyl estradiol + levonorgestrel, 255
ethinyl estradiol + norgestimate, 255
- Pharmacokinetics and pharmacodynamics,

Subject Index

- levonorgestrel (rat), 275
- levonorgestrel-releasing vaginal ring, 139
- norgestimate (rat), 275
- Pharmacological effects, low-dose combined OCs, 1
- Placental fibronectin, isolation and purification, 151
- Pregnancy termination,
 - misoprostol, 101
 - RU 486 + 9-methylene-PGE₂, 87
 - RU 44486 + misoprostol, 111
- Progestogens in OCs, 1
- Removal method NORPLANT® implants, 551
- RU 4486 (mifepristone),
 - effect on cervical smooth muscle, 115
 - effect on hormone levels, 245
 - serum and tissue levels, 245
- RU 486 + 9-methylene-PGE₂, 87
- RU 486 + misoprostol, 111
- Smoking vs nonsmoking women, effect of OCs on haemostasis profile, 579
- Spermicides, antiviral activity, 131
- Standard-dose vs low-dose OCs, 171
- Subdermal implants, levonorgestrel, 551, 557
- TCu380A, 543
- Toxicity studies,
 - estradiol cypionate + depot-medroxyprogesterone acetate, 335
 - estradiol valerate and norethisterone enanthate, 303
- Toxicology, DMPA, 189
- Vaginal ring, levonorgestrel-releasing, 139
- ZK 98.299 antiprogesterin, immunocytochemical study (monkey), 593